Frequently Asked Questions about Nuvalent, Inc. (NUVL)

Name: Nuvalent, Inc. (NUVL) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Nuvalent, Inc. (NUVL) do?

Accepted Answer

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and rem...

Question 2

Is Nuvalent, Inc. (NUVL) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of NUVL reveals an Altman Z-Score of 26.43 and a Piotroski F-Score of 1/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if NUVL fits their risk profile.

Question 3

What is the current P/E ratio for NUVL?

Accepted Answer

As of the latest trading session, Nuvalent, Inc. (NUVL) has a trailing P/E ratio of -18.55.

Question 4

Who is the CEO of Nuvalent, Inc.?

Accepted Answer

The current Chief Executive Officer of Nuvalent, Inc. is James R. Porter.

Question 5

What was NUVL's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Nuvalent, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does NUVL pay a dividend?

Accepted Answer

Nuvalent, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does NUVL have?

Accepted Answer

In its latest reporting period, Nuvalent, Inc. generated $-0.28B in Free Cash Flow against a total debt load of $N/A.

Question 8

What is the Price-to-Book (P/B) ratio of Nuvalent, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Nuvalent, Inc. (NUVL) is currently 6.32.

Question 9

What is the Price-to-Sales (P/S) ratio of NUVL?

Accepted Answer

Based on trailing twelve-month data, Nuvalent, Inc. (NUVL) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Nuvalent, Inc.'s Return on Equity (ROE)?

Accepted Answer

Nuvalent, Inc. (NUVL) has a Return on Equity (ROE) of -42.07%, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Net Debt
2025-12	1.4B	164.4M	1.2B	-261.7M
2024-12	1.1B	72M	1.1B	-145.7M
2023-12	732.4M	31.8M	700.6M	-335.4M
2022-12	482.5M	19.5M	463M	-241.8M
2021-12	293.8M	8.8M	285M	-68.5M

Period	Total Assets	Total Liabilities	Total Equity	Net Debt
2025-12	1.4B	164.4M	1.2B	-261.7M
2024-12	1.1B	72M	1.1B	-145.7M
2023-12	732.4M	31.8M	700.6M	-335.4M
2022-12	482.5M	19.5M	463M	-241.8M
2021-12	293.8M	8.8M	285M	-68.5M